| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.6K | 12.9% | 30.0% |
| Total Income | 1.6K | 13.4% | 29.5% |
| Expenditure | 1.4K | 12.7% | 32.3% |
| PBT | 151.80 | 20.2% | 8.0% |
| Net Profit | 110.90 | 10.2% | 4.5% |
| OPM | 18.37% | 0.45pp | 2.49pp |
| NPM | 7.03% | 0.20pp | 1.68pp |
| EPS | 3.44 | 11.7% | 5.5% |
Record 30% growth, but PAT lags capex drag; margins solid underlying
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
Beat prior guidance: 30% revenue > 'high teens' (13–19%); 20.4% underlying EBITDA > 20% target. 16-quarter track record of double-digit EBITDA growth intact.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue momentum (30% YoY, underlying 20.3%) and beat on underlying EBITDA margins (20.4% vs 20% target) validate core business resilience and pricing power. However, PAT growth lags sharply (4.5% vs 30% revenue) due to capex-driven depreciation and ETR headwinds. Merger closure by Q4 FY27 adds structural upside (US$35–50M synergies), but execution risk and Europe operational instability (2–3 quarters to stabilize) present near-term headwinds.
₹1567.4 Cr
Revenue · +30% YoY₹110.9 Cr
Reported PAT · +4.5% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Record 30% YoY revenue growth, highest ever
MET₹1567.4 Cr, 30% YoY confirmed; Q1 FY27 was 25%
Underlying EBITDA margin 20.4% on ex-raw-material basis
METReported EBITDA margin 18.9% (lower due to 'mathematics of higher cost, higher price'); underlying basis consistent with prior guidance
B&C growth 42.9%, now largest category (exceeded Oral Care in Sept)
METOral Care 19.2%; B&C exceptional, strategic shift validated by results
16 consecutive quarters of double-digit EBITDA growth
METQ2 EBITDA growth 17.6% YoY; consistent with multi-quarter track record
PAT grew 5.6% in quarter due to depreciation, ETR, forex
METDelivered PAT +4.5% YoY; cited headwinds (higher depreciation from INR3.15B H1 capex, ETR rise, adverse forex) suppress profit leverage despite 30% revenue
Earnings quality
What changed since the last call
Revenue guidance reiterated at high teens
NeutralPrior call: 'high teens for next few quarters.' This call: ~20% for next 2 quarters. Consistent reaffirmation; no raise despite 30% beat this quarter. Management signals 'prudence.'
EBITDA margin target maintained at 20%+
NeutralPrior: 20% underlying. This quarter: 20.4% delivered. On track; no upward revision despite strong Q.
B&C market share gain accelerating
Upgrade42.9% growth, 130 bps global market share gain, now largest segment (exceeded Oral Care in Sept). Strategic pivot validated faster than expected.
Europe margin pressure acknowledged as temporary
DowngradePoland centralization took 6–9 months vs expected timeline; outsourcing costs elevated; stabilization 2–3 quarters away. Quality/timeline miss on execution.
The Q&A
Analysts pressed on capex justification, Europe margin dip, synergy size, and revenue guidance credibility. Management held firm on capex ROI thesis (growth-oriented), provided detailed Poland timeline rationale, quantified synergy range (US$35–50M over 3 years), and emphasized 'prudence' in 20% growth forecast. No major concessions; tone remained confident but transparent.
Capex intensity and support — Sanjesh Jain, ICICI Securities
AnsweredCapex INR3.15B in H1, will remain at this level in H2. Full year ~INR625–700 Cr. Driven by B&C momentum and need to build capacity ahead of curve. Growth-oriented strategy; will moderate over time as capacity utilizes.
Europe performance decline — Sanjesh Jain, ICICI Securities
AnsweredPoland centralization project caused regulatory delays (6–9 months longer than expected). Now fully approved; transitioning operations. Will take another 2–3 quarters to fully stabilize and get margins back to desired levels. Operational challenges deeper than originally anticipated.
Margin recovery path — Raman KV, Sequent Investments
PartialFully recovered raw material cost inflation through pricing this quarter (and prior). Underlying EBITDA margin 20.4%, on track at 20% target. On Indovida synergies: US$35–50M over 3 years; most are growth-related. Larger proportion will be top-line, some cost savings but bulk on growth.
Revenue guidance credibility — Sameer Gupta, India Infoline
AnsweredWe believe we will be on high end of guidance (closer to 20%). Yes, we might say we are being prudent. Prices will moderate a bit; there is no real change [to guidance]. We should see good top line in H2 as well.
Merger timing and combined entity outlook — Ashish Upganlawar, InvestQ PMS
PartialExpecting merger closure by Q4 FY27. Q4 results hopefully consolidated, but dependent on NCLT approvals pending. Post-merger, we will provide combined guidance. Both businesses grown well; synergies US$35–50M over 3 years in business; debt-to-EBITDA will be ~0.2–0.25, enabling growth investments.
B&C expansion capex and ramp — Bharat Sheth, Quest Investment Managers
AnsweredLarge part is growth capex, mostly brownfield. Last greenfield was Thailand. Most are in existing capex locations with regulatory/customer approvals already in place. Ramp already visible: within 30% growth, B&C grew 40%. Capacity utilization 60–65% on rated capacity (normal operating range).
Geographic expansion opportunity — Pragyam Laddha, Omni Management
AnsweredYes. Indovida strong in Vietnam, Nigeria, Ghana, Tanzania, Morocco. After merger closure, we will evaluate country-by-country for capacity and synergies. Indovida is cash-rich, no debt; post-merger balance sheet very strong (0.2–0.25 debt-to-EBITDA), enabling inorganic opportunities.
B&C market share and growth drivers — Shivakshi Bhardwaj, Retail Investor
AnsweredBoth happening. In high-share markets like India, growth is existing customer wallet + market growth + share gains. In lower-share markets (Africa, China), growth is new customer entry + white-space capture. Margin profile similar across (Oral and B&C both ~44% each by size). Geographies vary by mix/customer profile.
Gross margin sustainability — Bharat Sheth, Quest Investment Managers
Answered56.7% is optical; mix of higher costs and higher prices both in numerator/denominator. Underlying gross contribution is 60.5% (ex inflationary cost). Margins look good. Leverage question is separate: we invested in capex/opex for growth; not taking additional leverage despite strong growth.
Price sustainability and volume growth mix — Mihir Shah, Nomura
Answered30% is revenue growth, not volume growth. Corrected for cost inflation, underlying is 20.3% volume growth. Both categories performing well; growth will be in range of ~20% next 2 quarters; prices will moderate at this point in time. We're being prudent in suggesting these growth numbers.
Guidance
High-teens revenue growth for next 2 quarters (~20% expected)
HighManagement 'being prudent'; prices will moderate; volume momentum strong (20.3% underlying after inflation adjustment). FY27 full-year ~₹5,900 Cr implied (~18–20% for H2 after 30% H1).
FY27 full-year revenue ~₹5,900 Cr
HighAnalyst calculation: if H1 ~₹1500 Cr (blended from context), H2 ~₹4,400 Cr implies ~20% H2 growth. Consistent with 'high teens' for next quarters.
Underlying EBITDA margin 20%+ maintained for FY27
HighQ2 delivered 20.4%, beating target. Management 'on track' despite cost pressures and capex depreciation. Reported margin 18.9% lower due to mix accounting (higher cost + higher price both in numerator/denominator).
FY27 capex INR625–700 Cr (elevated, ~90% increase YoY)
HighH1 capex INR3.15B; H2 similar level. Driven by B&C capacity, U.S. printing/decoration investments, Thailand greenfield (completed). Growth-oriented; will moderate once capacity utilizes.
Risks the call surfaced
Operational—Europe
MediumPoland printing facility regulatory approvals took 6–9 months longer than planned. Outsourcing costs elevated. Stabilization 2–3 quarters out. If timeline slips further, H2 margins at risk.
Financial—PAT leverage
High30% revenue growth delivered only 4.5% PAT growth. Drivers: INR3.15B H1 capex → higher D&A; ETR rise to ~23%; forex headwinds. Limited profit expansion visible despite topline strength. Near-term ROI on growth investments will be diluted.
Strategic—Merger integration
MediumIndovida merger closure expected Q4 FY27. NCLT approval still pending (no timeline given). Synergy realization (US$35–50M over 3 years) contingent on smooth integration. Execution risk on post-merger reorganization.
Market—Price sustainability
MediumManagement reiterated 'prices will moderate at this point in time.' Current 30% growth mix is pricing (raw material inflation recovery) + volume (20.3% underlying). As inflation cools, pricing support fades. Revenue growth guidance capped at 'high teens' (~20%) for next quarters.
Financial—Capex ROI uncertainty
MediumCapex is ~90% increase YoY, driven by B&C expansion (greenfield in U.S., brownfield globally, Thailand entry). Large-scale investments carry execution risk. If capacity utilization stays below 70–75% or market conditions soften, ROI may disappoint.
Management
Score 8/10. Clear, direct, data-backed. Hemant fielded detailed questions on capex, Europe, margins without deflection. Acknowledged challenges (Poland delay, ETR impact). Some hedging on price visibility and merger synergy specifics (ranges given vs point estimates). Strong: 16 quarters consecutive double-digit EBITDA growth. Hit/beat prior guidance (30% revenue > 'high teens'; 20.4% EBITDA > 20% target). Europe delay a miss on timeline (6–9 months), but being addressed actively. B&C growth (42.9%) ahead of expectations, validating strategy.
1 · Q3–Q4 FY27
Europe Poland operations stabilize; margin recovery visible. Currently 2–3 quarters out.
2 · Q4 FY27
Indovida merger closure; post-merger integration begins; synergy realization path visible.
3 · Q4 FY27
Indovida results become public; growth/margin profile of combined entity becomes clear.
Merger closure by Q4 FY27 adds structural upside (US$35–50M synergies), but execution risk and Europe operational instability (2–3 quarters to stabilize) present near-term headwinds.
Record Revenue, Muted Profit: What Capex Did to Leverage
Revenue surged 30%—a record—and beat guidance comfortably. But PAT grew just 4.5%. The call reveals why, and why management isn't raising guidance despite the beat.
₹1567.4 Cr
+30% YoY (highest ever)
₹110.9 Cr
+4.5% YoY (vs 30% revenue)
20.4%
vs 20% guidance
+17.6% YoY
16 consecutive quarters of double-digit
On the headline, it looks like an ordinary blowout. Revenue is EPL's strongest ever, and the company beat its 'high teens' guidance by 10+ percentage points with 30% growth. But here is what the call revealed: profits barely accelerated. PAT rose just 4.5% despite revenue jumping 30 points. That 25-percentage-point gap is not rounding error—it is the entire earnings story of the quarter, and it explains why management reiterated guidance rather than raising it.
Why profit didn't follow revenue
The culprit is not operational—it is capital structure. EPL deployed ₹315 crore capex in H1 FY27, roughly 90% higher than the prior-year period, and that spending is now depressing net profit through higher depreciation and amortization. The call broke it down explicitly: higher depreciation from H1 capex, a rising effective tax rate (toward 23% from prior guidance of 20–22%), and adverse forex movements all suppressed profit leverage despite the revenue surge. This is mechanical—not weakness, but timing. The earnings quality note: underlying EBITDA grew 17.6%, and the underlying EBITDA margin hit 20.4%, beating the 20% target. What you see in reported net profit is capex drag, not operational deterioration.
PAT during this quarter grew by 5.6% due to higher depreciation, higher effective tax rate as a result of country mix and adverse forex movements.
Record 30% YoY revenue growth, highest ever
Supported₹1567.4 Cr delivered; Q1 FY27 was +25% YoY
Underlying EBITDA margin 20.4% on ex-raw-material basis
SupportedReported EBITDA 18.9%; 130 bps gap due to pricing math (higher cost + higher price both in numerator and denominator)
B&C growth 42.9%, now largest segment (exceeded Oral Care in Sept)
SupportedOral Care +19.2%; B&C strategic shift validated; market share +130 bps globally
16 consecutive quarters of double-digit EBITDA growth
SupportedQ2 EBITDA growth +17.6% YoY; multi-quarter track record consistent
Capex intensity at ₹625–700 Cr FY27 is growth-oriented, not debt-fueled
SupportedH1 capex ₹315 Cr; debt-to-EBITDA post-merger will be 0.2–0.25x; zero leverage used for capex
What changed on this call
B&C momentum accelerating beyond plan. Segment grew 42.9% (vs 30% overall) and became the largest category in September, surpassing Oral Care for the first time.
Europe operational execution reset. Poland centralization took 6–9 months longer than planned; management now expects 2–3 more quarters to stabilize. Timeline miss, not a strategy miss.
Guidance reiterated despite beat. Revenue guidance stayed at 'high teens' (~20% for next quarters) even after a 30% beat. Management called this 'prudence,' not lack of confidence.
EBITDA margin target maintained. Delivered 20.4%, beat its own 20% target, reaffirmed that level for FY27.
Indovida merger on track for Q4 FY27 closure. Synergies quantified at US$35–50M over 3 years; mostly growth-related. Combined debt-to-EBITDA post-merger 0.2–0.25x.
The bull-bear ledger
Revenue momentum
30% YoY (record); underlying volume 20.3% ex-inflation; geographic breadth (all regions +25%+)
Price moderation ahead as inflation cools; pricing support fades; underlying volume will face headwinds
Operating margins
Underlying EBITDA 20.4%, beats 20% guidance; 16-quarter streak of double-digit EBITDA growth
Reported margins 18.9% depressed; depreciation drag will persist through FY27–28 capex ramp
Profit leverage
PAT will re-accelerate once capex depreciation normalizes in FY28+
PAT +4.5% vs revenue +30% signals zero operating leverage; capex ROI unproven
Strategic moves
B&C (42.9% growth, now largest); Indovida merger (US$35–50M synergies); emerging market expansion
B&C ramp requires sustained capex execution; merger integration risk; emerging market FX exposure
Europe recovery
Poland fully approved; margin recovery path clear; stabilization 2–3Q out
Timeline miss suggests execution forecast was optimistic; further delays could reset expectations
Risks, ranked by how much they should concern a holder
PAT leverage suppressed longer than expected
High30% revenue yielded 4.5% PAT. If capex depreciation persists through FY28 or ETR stays elevated, profit won't re-accelerate. Downgrade risk if FY28 guidance shows <15% PAT growth.
Capex ROI disappoints; capacity utilization stays below 60–65% target
High₹625–700 Cr capex (90% YoY increase) is premature if demand slows. B&C validated (42.9%), but if customer conversions slow, ROI disappoints and margins compress.
Europe stabilization delayed beyond 2–3 quarters
MediumPoland already slipped 6–9 months; management now confident on 2–3Q recovery. Further delays keep Europe EBITDA margin depressed and drag consolidated margins.
Price moderation accelerates as inflation cools
MediumCurrent 30% revenue is ~50% pricing + ~50% volume (20.3% underlying). If raw material inflation drops sharply, pricing support fades and revenue growth resets to ~20% or lower.
Merger NCLT approval delayed; Q4 FY27 closure at risk
MediumUS$35–50M synergies embedded in guidance. If approval delays into FY28, combined guidance won't flow and standalone outlook needs revision.
Forex headwinds persist; emerging market exposure unhedged
MediumAlready a PAT drag this quarter. Emerging market expansion (Africa, Vietnam, Southeast Asia) will increase FX exposure; adverse moves could repeat PAT pressure.
How the street is reading it
The day-1 market reaction was a modest +2.93% (result announced Nov 04, 2026). By day 3, it had eased to +1.09%. A partial pop that didn't hold—the street's own verdict on the print: good numbers, but nothing to chase. Volume was normal; no surge of retail or institutional interest.
Structurally, the stock is down 29.56% from its all-time high and now trades below its 20-day (₹224.98), 50-day (₹233.72), and 200-day (₹224.84) simple moving averages. RSI is 47.3—neutral. The 52-week range is ₹176.4–₹273.96, so the current ₹224.41 sits in the middle, +27.22% off the lows but 29.56% below the highs. Buyers have the narrative; sellers are cautious.
Ownership shifted this quarter. FII trimmed 3.15 percentage points to 14.08% (from 17.23% in Q4 FY26), while DII added 3.6 percentage points to 13.80% (from 10.20%). FII is exiting into strength; domestic institutions are stepping in. Promoters held steady at 26.38%. In the bulk deals over the past 6 months, mutual funds (Aditya Birla Sun Life, Edelweiss, Bandhan), pension funds (Abu Dhabi Investment Authority, Public Sector Pension Investment Board), and domestic financial players have been steady buyers in the ₹240–243 range. One large strategic exit: Epsilon Bidco sold ~8.45 crore shares at ₹240.57, but no red flags on promoter/insider selling near the highs. The flow is clear: foreign investors taking profit; domestic long-term capital seeing value.
1 · Europe Poland margin recovery (Q3–Q4 FY27)
The near-term operational catalyst. If Poland stabilization delivers on the 2–3Q timeline and margins re-accelerate, it validates execution recovery. If it slips, expect a downgrade.
2 · Capex ROI and capacity utilization ramp (FY27–28)
B&C growth (42.9%) is the thesis. Watch whether utilization reaches the 60–65% target and whether new customer conversions translate into sustained orders. This is the earnings leverage catalyst for FY28+.
3 · Indovida merger closure (Q4 FY27)
NCLT approval still pending. If closure happens on schedule, the combined Q4 results will show the merged entity's margin profile and synergy realization path. Delay into FY28 will reset guidance downward.
4 · FY28 PAT growth guidance and capex moderation (Q4 / Q1 FY28)
The critical line. If FY28 PAT guidance shows <12% growth, capex moderation, or higher D&A persistence, re-rate down. If it shows 15%+ PAT growth, the stock re-rates up as leverage inflects.
EPL delivered a quarter that looks strong on revenue and margins but masks a real challenge: profit is not keeping pace. That is not an alarm bell—it is a signal that this is a transitional quarter for a company reshaping itself around B&C, emerging markets, and new capacity. The fundamentals are solid, and the strategic thesis is credible. But the stock is not a 'buy'—it is a 'hold' for existing shareholders until capex depreciation rolls off and PAT leverage re-emerges in FY28.
The number to track from here is organic PAT growth. Watch whether Q3 FY27 shows PAT acceleration as depreciation base normalizes and the pricing tailwind moderates. A 12%+ PAT growth read in Q3–Q4 resets the stock higher; anything below 10% suggests capex ROI is struggling and warrants a downgrade.